Advertisment
AstraZeneca Set to Reveal New Data on Immunotherapies and Vaccines at Upcoming IDWeek 2024
AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 October 2024. The Company will highlight progress in advancing novel immunisations against infectious diseases of high unmet need and share real-world evidence showing the burden of respiratory viral infections and the continued need for protection.
Iskra Reic, Executive Vice President of Vaccines & Immune Therapies, AstraZeneca, said: “The data being presented at IDWeek demonstrate our commitment to addressing the impact of infectious diseases, notably our progress in developing our vaccine and antibody candidates against viral and bacterial pathogens, including IVX-A12, the first potential combination RSV/hMPV vaccine, and AZD5148 against C. diff infections. The advancement of IVX-A12 builds on our scientific leadership in RSV, with data being presented on Beyfortus demonstrating how, in its first season, it has delivered significant real-world impact in protecting a broad infant population against the disease, with millions more children set to benefit this season.”
Data in RSV, combination vaccines, C. diff and influenza
Data will be presented on Beyfortus (nirsevimab), AstraZeneca’s long-acting antibody for the prevention of RSV disease, showing that Beyfortus does not interfere with RSV detection by rapid antigen tests enabling accurate diagnosis to support clinical management.10 Additional data, presented by our partner Sanofi, confirm the significant real-world effectiveness of Beyfortus in reducing RSV disease and hospitalisations in infants. These data build on recent evidence, including from the US Advisory Committee on Immunisation Practices, demonstrating Beyfortus was associated with a 90% reduction in RSV-associated hospitalisations in its first season.
Interim Phase II data on IVX-A12, an investigational combination virus-like particle vaccine, will be presented, demonstrating that IVX-A12 was well-tolerated and immunogenic against both RSV and hMPV in older adults 60 to 85 years of age.6,7
Pre-clinical data will be shared showing that AZD5148, an anti-toxin B neutralizing monoclonal antibody now in Phase I trials, may provide protection against Clostridioides difficile (C. diff) infection, a condition that can cause life-threatening diarrhea and intestinal inflammation.9
Additionally, AstraZeneca is presenting vaccine effectiveness data for FluMist (live attenuated influenza vaccine), recently approved in the US as the only vaccine for self- or caregiver administration for the prevention of influenza.8
Real-world evidence shows the need for protection against respiratory viral infections
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are in the same family of respiratory viruses and can cause serious respiratory infections, especially in children, older adults and those with co-morbid conditions.1 AstraZeneca will present data highlighting the seasonal patterns of hMPV and RSV, reflecting a return to pre-pandemic seasonality. Overlapping seasonal patterns of hMPV and RSV were seen in most countries, underscoring the importance of continued surveillance during the coming season and the potential benefit of a combination vaccine that offers protection against both viruses.2
Additional findings analysed hMPV outcomes in nursing homes, indicating that in high-risk older adults, hMPV outcomes of hospitalisation and death were comparable with influenza.3 These analyses highlight the risk that hMPV can present to high-risk older adults living in nursing homes and the need for advancements in testing and prevention.3
Updated data from INFORM, a retrospective health database observational study in England, highlight the continued burden of COVID-19 on immunocompromised patients.4,5 Findings show the continued increased risk of COVID-19 hospitalisation and death in immunocompromised patients despite receiving ≥4 vaccine doses, as well as consistently showing higher COVID-19 mortality among hospitalised immunocompromised individuals compared to non-immunocompromised individuals.4,5
Key AstraZeneca presentations during IDWeek 2024
| Abstract Title | Presentation Details |
| IVX-A12 | |
| Safety and immunogenicity of a Respiratory Syncytial Virus and human Metapneumovirus virus-like particle protein subunit combination vaccine in 60–85-year-old adults: interim results from a Phase 2a clinical trial | Poster Presentation
Session Title: New Vaccines |
| Human Metapneumovirus (hMPV) Real-World Evidence | |
| Global surveillance of human Metapneumovirus (hMPV) and Respiratory Syncytial Virus (RSV) epidemiology since 2022 | Poster Presentation
Session Title: Virology: Epidemiology of Viral Infections Date: Saturday, October 19, 2024 Time: 12:15 PM – 1:30 PM PT Location: Halls J & K |
| Outcomes of human Metapneumovirus in nursing home residents: a matched analysis | Poster Presentation
Session Title: HAIs: Non-Acute Care |
| COVID-19 Real World Evidence | |
| Individuals on immunosuppressive or immunomodulatory therapies remain at increased risk of COVID-19 hospitalization, despite vaccination: findings from INFORM, a retrospective health database study in England | Poster Presentation
Session Title: Covid-19: Special Populations |
| COVID-19 mortality among immunocompromised individuals is consistently high compared with non-immunocompromised individuals: results of the INFORM study, England | Poster Presentation
Session Title: Covid-19: Special Populations |
| Beyfortus (nirsevimab) | |
| Nirsevimab in patient samples does not interfere with Respiratory Syncytial Virus (RSV) detection by commercially available rapid antigen tests | Poster Presentation
Session Title: Diagnostics: Virology |
| FluMist | |
| Effectiveness of live attenuated and inactivated influenza vaccines in children: data from the 2023/24 influenza season | Poster Presentation
Session Title: Pediatric Vaccines Date: Thursday, October 17, 2024 Time: 12:15 PM –1:30 PM PT Location: Halls J & K |
| Early Science | |
| Anti-toxin B neutralizing monoclonal antibody AZD5148 provides protection in a clostridioides difficile gnotobiotic piglet model | Poster Presentation
Session Title: New Drug Development |
| Lower Respiratory Tract Disease Real-World Evidence | |
| A need for infection prevention among patients with ESKD on maintenance dialysis: a first step in understanding how SARS-CoV-2 impacts this population
|
Poster Presentation
Session Title: HAIs: Surveillance Date: Thursday, October 18, 2024 Time: 12:15 PM – 1:30 PM PT Location: Halls J & K |
| Global incidence of viral lower respiratory tract disease (LRTD) episodes and hospitalizations (2010-2021) | Oral Presentation
Session Title: Navigating Acute Respiratory Infections |
